

Author index

Volume 252 (1996)

- Anderson, G.J., see Marway, J.S. 252, 123
 Arnal, M. see Egerland, A. 252, 51
- Bayçu, C. see Kanbak, G. 252, 61
 Bhaggoe, U.M. see Boomsma, F. 252, 41
 Blache, D. see Durand, P. 252, 83
 Bonner, A.B. see Marway, J.S. 252, 123
 Boomsma, F., U.M. Bhaggoe, A.J. Man in 't Veld, M.A.D.H. Schalekamp, Comparison of N-terminal pro-atrial natriuretic peptide and atrial natriuretic peptide in human plasma as measured with commercially available radioimmunoassay kits 252, 41
 Bouwman, D.L. see Tessier, A.J. 252, 11
 Braganza, J.M., see Gu, M. 252, 181
 Briand, G., see Fontaine, M. 252, 109
 Bueno, M., see Sarria, A. 252, 21
- Capra, F., see Gabrielli, G.B. 252, 171
 Carrascosa, D. see De la Torre, R. 252, 205
 Casado, A. see De la Torre, R. 252, 205
 Casaril, M. see Gabrielli, G.B. 252, 171
 Cavari, S., S. Vannucchi, Detection of heparin-like glycosaminoglycans in normal human plasma by polyacrylamide-gel electrophoresis 252, 159
 Colombari, R. see Gabrielli, G.B. 252, 171
 Corrocher, R. see Gabrielli, G.B. 252, 171
- Davignon, J. see Durand, P. 252, 83
 Degand, P. see Fontaine, M. 252, 109
 De la Torre, R. A. Casado, D. Carrascosa, M.E. López-Fernández, Cu/Zn superoxide dismutase overproduction in mentally retarded (non-Down) patients 252, 205
- De Sandre, G. see Gabrielli, G.B. 252, 171
 Dicostanzo, J. Egerland, A. 252, 51
 Divry, P., see Fontaine, M. 252, 109
 Dombi, G.W., see Tessier, A.J. 252, 11
 Dorizzi, M., see Giavarina, D. 252, 209
 Durand, P., L.J. Fortin, S. Lussier-Cacan, J. Davignon, D. Blache, Hyperhomocysteinemia induced by folic acid deficiency and methionine load — applications of a modified HPLC method 252, 83
- Egerland, A., J.P. Reynier, O. Ballevre, J. Dicostanzo, C. Obled, M. Arnal, Protein synthesis measurement in cancer patients with ¹³C valine 252, 51
- Fontaine, M., G. Briand, L. Vallée, G. Ricart, P. Degand, P. Divry, C. Vianey-Saban, J. Vamecq, Acylcarnitine removal in a patient with acyl-CoA β -oxidation deficiency disorder: effect of L-carnitine therapy and starvation 252, 109
 Fortin, L.J., see Durand, P. 252, 83
 Furukawa, A., see Iwahashi, K. 252, 197
- Gabrielli, G.B., F. Capra, M. Casaril, R. Corrocher, R. Colombari, G. De Sandre, Serum laminin P1 in chronic viral hepatitis: correlations with liver histological activity and diagnostic value 252, 171
 Giavarina, D., R.M. Dorizzi, P. Moghetti, Fasting plasma glucose and diabetes diagnosis 252, 209
 Gibbons, W.A., see Marway, J.S. 252, 123
 Giner, A., see Sarria, A. 252, 21
 Gips, C.H., see Huizenga, J.R. 252, 73

- Grimble, G.K., see Marway, J.S. 252, 123
- Gu, M., H. Love, D. Schofield, W. Turkie, N. Odom, J.M. Braganza, A pilot study of blood antioxidant and free radical marker profiles in patients awaiting coronary artery bypass grafting 252, 181
- Hashimoto, H., T. Mio, K. Sumino, Lipid abnormalities of erythrocyte membranes in hemodialysis patients with chronic renal failure 252, 137
- Huizenga, J.R., G.M. van Dam, C.H. Gips, Arterial ammonia with Blood Ammonia Checker II and with indophenol reaction to assess presence of hepatic encephalopathy 252, 73
- Ichikawa, Y., see Iwahashi, K. 252, 197
- İnal, M., see Kanbak, G. 252, 61
- Iwahashi, K., E. Okuyama, A. Furukawa, K. Nakamura, R. Miyatake, Y. Matsuo, Y. Ichikawa, Novel 2-point linked mutations in the 5'-flanking region of human CYP2C18 252, 197
- Kanbak, G., M. İnal, C. Bayçu, The role of free radicals in *p*-aminophenol-induced nephrotoxicity: does reduced glutathione have a protective effect? 252, 61
- Kawasaki, H., see Yamada, S. 252, 95
- Keusch, J., Y. Levy, Y. Shoenfeld, P. Youinou, Analysis of different glycosylation states in IgG subclasses 252, 147
- Kobayashi, J., see Yamada, S. 252, 95
- Kobayashi, S., see Tateishi, T. 252, 1
- Kumai, T., see Tateishi, T. 252, 1
- Lasierra, M.P., see Sarria, A. 252, 21
- Larrad, L., see Sarria, A. 252, 21
- Lázaro, A., see Sarria, A. 252, 21
- Levy, Y., see Keusch, J. 252, 147
- López-Fernández, M.E., see De la Torre, R. 252, 205
- Love, H., see Gu, M. 252, 181
- Lussier-Cacan, S., see Durand, P. 252, 83
- Man in 't Veld, A.J., see Boomsma, F. 252, 41
- Marway, J.S., G.J. Anderson, J.P. Miell, R. Ross, G.K. Grimble, A.B. Bonner, W.A. Gibbons, T.J. Peters, V.R. Preedy, Application of proton NMR spectroscopy to measurement of whole-body RNA degradation rates: effects of surgical stress in human patients 252, 123
- Matsuo, Y., see Iwahashi, K. 252, 197
- Miell, J.P., see Marway, J.S. 252, 123
- Mio, T., see Hashimoto, H. 252, 137
- Miyatake, R., see Iwahashi, K. 252, 197
- Moggetti, P., see Giavarina, D. 252, 209
- Moreno, L.A., see Sarria, A. 252, 21
- Morris, B.J., see Robert, Y.L. 252, 33
- Mur, M., see Sarria, A. 252, 21
- Murawaki, Y., see Yamada, S. 252, 95
- Nakura, H., see Tateishi, T. 252, 1
- Nakamura, K., see Iwahashi, K. 252, 197
- Obled, C., see Egerland, A. 252, 51
- Odom, N., see Gu, M. 252, 181
- Okuyama, E., see Iwahashi, K. 252, 197
- Peters, T.J., see Marway, J.S. 252, 123
- Preedy, V.R., see Marway, J.S. 252, 123
- Reynier, J.P., see Egerland, A. 252, 51
- Ricart, G., see Fontaine, M. 252, 109
- Roda, L., see Sarria, A. 252, 21
- Ross, R., see Marway, J.S. 252, 123
- Sarria, A., L.A. Moreno, M. Mur, A. Lázaro, M.P. Lasierra, L. Roda, A. Giner, L. Larrad, M. Bueno, Relationship between immunoinflammatory proteins containing sialic acid and low-density lipoprotein serum concentrations 252, 21
- Schalekamp, M.A.D.H., see Boomsma, F. 252, 41
- Schofield, D., see Gu, M. 252, 181
- Schrader, A.P., see Zee, R.Y.L. 252, 33
- Shoenfeld, Y., see Keusch, J. 252, 147
- Sumino, K., see Hashimoto, H. 252, 137
- Suou, T., see Yamada, S. 252, 95
- Tanaka, M., see Tateishi, T. 252, 1
- Tateishi, T., H. Nakura, M. Watanabe, M. Tanaka, T. Kumai, S. Kobayashi, Preliminary examination of the influence of incubation time or cytosolic protein concentration on dihydropyrimidine dehydrogenase activity 252, 1
- Tein, I., Z.-W. Xie, The human plasmalemmal carnitine transporter defect is expressed in cultured lymphoblasts: a new non-invasive method for diagnosis 252, 201
- Tessier, A.J., G.W. Dombi, D.L. Bouwman, Thermostability of purified human pancreatic α -amylase is increased by the combination of Ca^{2+} and human serum albumin 252, 11

- Turkie, W., see Gu, M. 252, 181
- Vallée, L., see Fontaine, M. 252, 109
- van Dam, G.M., see Huizenga, J.R. 252, 73
- Vannucchi, S., see Cavari, S. 252, 159
- Vianey-Saban, C., see Fontaine, M. 252, 109
- Vamecq, J., see Fontaine, M. 252, 109
- Watanabe, M., see Tateishi, T. 252, 1
- Xie, Z.-W., see Tein, I. 252, 201
- Yamada, S., J. Kobayashi, Y. Murawaki, T. Suou, H. Kawasaki, Collagen-binding activity of plasma vitronectin in chronic liver disease 252, 95
- Youinou, P., see Keusch, J. 252, 147
- Zee, R.Y.L., A.P. Schrader, B.J. Morris, Effect of angiotensin-converting enzyme genotype on renin-angiotensin components in hypertensives 252, 33



Subject index

Volume 252 (1996)

Acylcarnitine; Deficient mitochondrial β -oxidation; Mass spectrometry; L-Carnitine; Starvation 252, 109

Alpha-amylase; Amylases; Calcium; Kinetics; Metalloproteins; Serum albumin; Thermodynamics 252, 11

p-Aminophenol; Superoxide dismutase; Catalase; Glutathione peroxidase; Glutathione reductase; Reduced glutathione; Malondialdehyde 252, 61

Ammonia; Blood; Methods; Hepatic encephalopathy 252, 73

Amylases; Alpha-amylase; Calcium; Kinetics; Metalloproteins; Serum albumin; Thermodynamics 252, 11

Angiotensinogen, plasma; Renin, plasma; Angiotensin-converting enzyme, plasma; Polymerase chain reaction; Insertion/deletion polymorphism; Met²³⁵ \rightarrow Thr polymorphism; Molecular genetics; Blood pressure (human) 252, 33

Angiotensin-converting enzyme, plasma; Renin, plasma; Angiotensinogen, plasma; Polymerase chain reaction; Insertion/deletion polymorphism; Met²³⁵ \rightarrow Thr polymorphism; Molecular genetics; Blood pressure (human) 252, 33

Antioxidant prophylaxis; Post-coronary artery bypass grafting (post-CABG) pancreatitis; Oxidative stress 252, 181

Atherosclerosis; Homocysteine; Folic acid deficiency; Methionine load 252, 83

Antithrombin III; Plasma; Heparin; Electrophoresis 252, 159

Atrial natriuretic peptide; N-Terminal pro-atrial natriuretic peptide; Radioimmunoassay; Human plasma 252, 41

Blood; Ammonia; Methods; Hepatic encephalopathy 252, 73

Blood pressure (human); Renin, plasma; Angiotensinogen, plasma; Angiotensin-converting enzyme, plasma; Polymerase chain reaction; Insertion/deletion polymorphism; Met²³⁵ \rightarrow Thr polymorphism; Molecular genetics 252, 33

Calcium; Alpha-amylase; Amylases; Kinetics; Metalloproteins; Serum albumin; Thermodynamics 252, 11

Cancer; Parenteral nutrition; Protein synthesis; Stable isotope 252, 51

L-Carnitine; Acylcarnitine; Deficient mitochondrial β -oxidation; Mass spectrometry; Starvation 252, 109

Carnitine transport; Cultured human lymphoblasts; Primary carnitine deficiency; Fatty acid oxidation 252, 201

- Children;** Immunoglobulins; Complement components; Glycoproteins; Low density lipoprotein cholesterol; Atherosclerosis **252, 21**
- Chronic hepatitis;** Serum laminin; Chronic hepatitis; Chronic liver disease; Cirrhosis; Diagnostic value; Histological correlations **252, 171**
- Chronic liver disease;** Vitronectin; Collagen; Chronic liver disease **252, 95**
- Chronic liver disease;** Vitronectin; Collagen; **252, 95**
- Cirrhosis;** Serum laminin; Chronic hepatitis; Chronic liver disease; Diagnostic value; Histological correlations **252, 171**
- Collagen;** Vitronectin; Chronic liver disease **252, 95**
- Complement components;** Immunoglobulins; Glycoproteins; Low density lipoprotein cholesterol; Children; Atherosclerosis **252, 21**
- Cultured human lymphoblasts;** Carnitine transport; Primary carnitine deficiency; Fatty acid oxidation **252, 201**
- Alpha-amylase;** Amylases; Calcium; Kinetics; Metalloproteins; Serum albumin; Thermodynamics **252, 11**
- Deficient mitochondrial β -oxidation;** Acylcarnitine; Mass spectrometry; L-Carnitine; Starvation **252, 109**
- Diabetes mellitus;** Diagnostic criteria; Glucose tolerance test; Fasting plasma glucose; Likelihood ratio; Information theory **252, 209**
- Diagnostic criteria;** Diabetes mellitus; Glucose tolerance test; Fasting plasma glucose; Likelihood ratio; Information theory **252, 209**
- Diagnostic value;** 5-Fluorouracil; Dihydropyrimidine dehydrogenase; Incubation time; Cytosolic protein; Substrate concentration **252, 1**
- Dihydropyrimidine dehydrogenase;** 5-Fluorouracil; Incubation time; Cytosolic protein; Substrate concentration **252, 1**
- Enzyme-linked lectin assay;** Glycosylation; IgG subclasses; Lectins **252, 147**
- Erythrocyte membranes;** Lipid peroxidation; Hemodialysis; 7-Keto cholestadiene; GC/MS **252, 137**
- Fasting plasma glucose;** Carnitine transport; Cultured human lymphoblasts; Primary carnitine deficiency; Fatty acid oxidation **252, 201**
- Fatty acid oxidation;** Carnitine transport; Cultured human lymphoblasts; Primary carnitine deficiency **252, 201**
- 5-Fluorouracil;** Dihydropyrimidine dehydrogenase; Incubation time; Cytosolic protein; Substrate concentration **252, 1**
- Folic acid deficiency;** Homocysteine; Methionine load; Atherosclerosis **252, 83**
- GC/MS;** Lipid peroxidation; Hemodialysis; Erythrocyte membranes; 7-Keto cholestadiene **252, 137**
- Glucose tolerance test;** Diabetes mellitus; Diagnostic criteria; Fasting plasma glucose; Likelihood ratio; Information theory **252, 209**
- Glutathione peroxidase;** *p*-Aminophenol; Superoxide dismutase; Catalase; Glutathione reductase; Reduced glutathione; Malondialdehyde **252, 61**
- Glutathione reductase;** *p*-Aminophenol; Superoxide dismutase; Catalase; Glutathione peroxidase; Reduced glutathione; Malondialdehyde **252, 61**
- Glycoproteins;** Immunoglobulins; Complement components; Low density lipoprotein cholesterol; Children; Atherosclerosis **252, 21**
- Glycosylation;** Enzyme-linked lectin assay; IgG subclasses; Lectins **252, 147**
- Hemodialysis;** Lipid peroxidation; Erythrocyte membranes; 7-Keto cholestadiene; GC/MS **252, 137**
- Heparin;** Plasma; Antithrombin III; Electrophoresis **252, 159**
- Histological correlations;** Serum laminin; Chronic hepatitis; Chronic liver disease; Cirrhosis; Diagnostic value; **252, 171**

- Homocysteine;** Folic acid deficiency; Methionine load; Atherosclerosis 252, 83
- Human plasma;** N-Terminal pro-atrial natriuretic peptide; Atrial natriuretic peptide; Radioimmunoassay; 252, 41
- IGF-I;** Proton nuclear magnetic resonance; Urine; RNA catabolites; Surgical stress 252, 123
- IgG subclasses;** Enzyme-linked lectin assay; Glycosylation; Lectins 252, 147
- Incubation time;** 5-Fluorouracil; Dihydropyrimidine dehydrogenase; Cytosolic protein; Substrate concentration 252, 1
- Information theory;** Diabetes mellitus; Diagnostic criteria; Glucose tolerance test; Fasting plasma glucose; Likelihood ratio; 252, 209
- Insertion/deletion polymorphism;** Renin, plasma; Angiotensinogen, plasma; Angiotensin-converting enzyme, plasma; Polymerase chain reaction; Met²³³ → Thr polymorphism; Molecular genetics; Blood pressure (human) 252, 33
- Immunoglobulins;** Complement components; Glycoproteins; Low density lipoprotein cholesterol; Children; Atherosclerosis 252, 21
- 7-Keto cholestadiene;** Lipid peroxidation; Hemodialysis; Erythrocyte membranes; GC/MS 252, 137
- Kinetics;** Alpha-amylase; Amylases; Calcium; Metalloproteins; Serum albumin; Thermodynamics 252, 11
- Lectins;** Enzyme-linked lectin assay; Glycosylation; IgG subclasses 252, 147
- Likelihood ratio;** Diabetes mellitus; Diagnostic criteria; Glucose tolerance test; Fasting plasma glucose; Information theory 252, 209
- Lipid peroxidation;** Hemodialysis; Erythrocyte membranes; 7-Keto cholestadiene; GC/MS 252, 137
- Low density lipoprotein cholesterol;** Immunoglobulins; Complement components; Glycoproteins; Children; Atherosclerosis 252, 21
- Malondialdehyde;** p-Aminophenol; Superoxide dismutase; Catalase; Glutathione peroxidase; Glutathione reductase; Reduced glutathione 252, 61
- Mass spectrometry;** Acylcarnitine; Deficient mitochondrial β -oxidation; L-Carnitine; Starvation 252, 109
- Metalloproteins;** Alpha-amylase; Amylases; Calcium; Kinetics; Serum albumin; Thermodynamics 252, 11
- Methionine load;** Homocysteine; Folic acid deficiency; Atherosclerosis 252, 83
- Methods;** Blood; Ammonia; Hepatic encephalopathy 252, 73
- Met²³³ → Thr polymorphism;** Renin, plasma; Angiotensinogen, plasma; Angiotensin-converting enzyme, plasma; Polymerase chain reaction; Insertion/deletion polymorphism; Molecular genetics; Blood pressure (human) 252, 33
- Molecular genetics;** Renin, plasma; Angiotensinogen, plasma; Angiotensin-converting enzyme, plasma; Polymerase chain reaction; Insertion/deletion polymorphism; Met²³³ → Thr polymorphism; Blood pressure (human) 252, 33
- N-Terminal pro-atrial natriuretic peptide;** Atrial natriuretic peptide; Radioimmunoassay; Human plasma 252, 41
- Oxidative stress;** Post-coronary artery bypass grafting (post-CABG) pancreatitis; Antioxidant prophylaxis 252, 181
- Parenteral nutrition;** Cancer; Protein synthesis; Stable isotope 252, 51
- Plasma;** Heparin; Antithrombin III; Electrophoresis 252, 159
- Polymerase chain reaction;** Renin, plasma; Angiotensinogen, plasma; Angiotensin-converting enzyme, plasma; Insertion/deletion polymorphism; Met²³³ → Thr polymorphism; Molecular genetics; Blood pressure (human) 252, 33

- Post-coronary artery bypass grafting (post-CABG) pancreatitis;** Oxidative stress; Antioxidant prophylaxis **252, 181**
- Primary carnitine deficiency;** Carnitine transport; Cultured human lymphoblasts; Fatty acid oxidation **252, 201**
- Protein synthesis;** Parenteral nutrition; Cancer; Stable isotope **252, 51**
- Proton nuclear magnetic resonance;** Urine; RNA catabolites; IGF-I; Surgical stress **252, 123**
- Radioimmunoassay;** N-Terminal pro-atrial natriuretic peptide; Atrial natriuretic peptide; Human plasma **252, 41**
- Reduced glutathione;** *p*-Aminophenol; Superoxide dismutase; Catalase; Glutathione peroxidase; Glutathione reductase; Malondialdehyde **252, 61**
- Renin, plasma;** Angiotensinogen, plasma; Angiotensin-converting enzyme, plasma; Polymerase chain reaction; Insertion/deletion polymorphism; Met²³⁵ → Thr polymorphism; Molecular genetics; Blood pressure (human) **252, 33**
- RNA catabolites;** Proton nuclear magnetic resonance; Urine; IGF-I; Surgical stress **252, 123**
- Serum albumin;** Alpha-amylase; Amylases; Calcium; Kinetics; Metalloproteins; Thermodynamics **252, 11**
- Serum laminin;** Chronic hepatitis; Chronic liver disease; Cirrhosis; Diagnostic value; Histological correlations **252, 171**
- Stable isotope;** Parenteral nutrition; Cancer; Protein synthesis; **252, 51**
- Starvation;** Acylcarnitine; Deficient mitochondrial β -oxidation; Mass spectrometry; L-Carnitine **252, 109**
- Substrate concentration;** 5-Fluorouracil; Dihydropyrimidine dehydrogenase; Incubation time; Cytosolic protein **252, 1**
- Superoxide dismutase;** *p*-Aminophenol; Catalase; Glutathione peroxidase; Glutathione reductase; Reduced glutathione; Malondialdehyde **252, 61**
- Surgical stress;** Proton nuclear magnetic resonance; Urine; RNA catabolites; IGF-I **252, 123**
- Thermodynamics;** Alpha-amylase; Amylases; Calcium; Kinetics; Metalloproteins; Serum albumin **252, 11**
- Urine;** Proton nuclear magnetic resonance; RNA catabolites; IGF-I; Surgical stress **252, 123**
- Vitronectin;** Collagen; Chronic liver disease **252, 95**

